cisplatin and gemcitabine plus trastuzumab in treating patients with stage iiib or stage iv non-small cell lung cancer

Conditions: Lung Cancer

Summary: rationale: drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. monoclonal antibodies such as trastuzumab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. combining chemotherapy with monoclonal antibody therapy may kill more tumor cells. purpose: phase ii trial to study effectiveness of combining cisplatin, gemcitabine, and trastuzumab in treating patients who have stage iiib or stage iv non-small cell lung cancer.

objectives: i. determine the therapeutic efficacy and toxicity of cisplatin, gemcitabine, and trastuzumab (herceptin) in patients with untreated p185-her2 overexpressing stage iiib or iv non-small cell lung cancer. ii. determine the pharmacokinetic interactions among these drugs in these patients. iii. assess the pharmacodynamics of these drugs in these patients. outline: this is a multicenter study. regimen a: patients receive gemcitabine iv over 30 minutes followed by cisplatin iv over 2 hours on day 1 and trastuzumab (herceptin) iv over 90 minutes on day 2. patients receive trastuzumab iv over 90 minutes followed by gemcitabine iv over 30 minutes on day 8 and trastuzumab iv over 90 minutes on day 15. patients proceed to regimen b on day 22 of regimen a. regimen b: patients receive trastuzumab iv over 30-90 minutes, gemcitabine iv over 30 minutes, and cisplatin iv over 2 hours on day 1. patients receive trastuzumab iv over 30-90 minutes followed by gemcitabine iv over 30 minutes on day 8 and trastuzumab iv over 30-90 minutes on day 15. treatment repeats every 21 days for up to 5 courses in the absence of disease progression or unacceptable toxicity. maintenance: after completion of 6 courses, patients with stable disease or partial response receive trastuzumab iv over 30-90 minutes weekly until tumor progression. projected accrual: a total of 20-48 patients will be accrued for this study.

Eligibility criteria:
disease characteristics: immunohistochemically confirmed p185-her2 expressing stage iiib (pleural effusions only) or iv non-small cell lung cancer confirmed overexpression at least: 1+ p185-her2 (by dako hercep test) or 15 ng/ml serum her2/neu shed antigen (by human her2 quantitative elisa) at least 1 site of measurable disease outside of prior radiation port brain metastases allowed provided clinical neurologic status is stable and head ct scan is stable to improved patient characteristics: age: over 18 performance status: zubrod 0-2 life expectancy: more than 12 weeks hematopoietic: wbc at least 3,000/mm3 absolute neutrophil count at least 1,500/mm3 platelet count at least 100,000/mm3 hemoglobin at least 10 g/dl (transfusion allowed) hepatic: bilirubin less than 1.5 mg/dl sgpt no greater than 1.5 times normal renal: creatinine clearance at least 60 ml/min cardiovascular: no myocardial infarction within the past 6 months no unstable angina, uncontrolled congestive heart failure, or uncontrolled arrhythmia ejection fraction at least 40% other: no other malignancy within the past 5 years no concurrent serious infection, including post-obstructive pneumonia no more than 10% weight loss in past 3 months not pregnant or nursing negative pregnancy test fertile patients must use adequate contraception prior concurrent therapy: biologic therapy: not specified chemotherapy: no prior chemotherapy no other concurrent chemotherapy endocrine therapy: not specified radiotherapy: see disease characteristics at least 3 weeks since prior radiotherapy (including radiotherapy for brain metastases) no concurrent radiotherapy to only site of measurable disease surgery: at least 2 weeks since prior major surgery no concurrent surgery on only site of measurable disease

Keywords: stage iiib non-small cell lung cancer stage iv non-small cell lung cancer